Dishman Carbogen Amcis Limited (DCAL.BO)
INR 274.5
(-3.18%)
INR 274.5
(-3.18%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.45 Billion INR | -82.08% |
| 2022 | 13.7 Billion INR | 23.44% |
| 2021 | 11.1 Billion INR | 27.74% |
| 2020 | 8.69 Billion INR | 82.1% |
| 2019 | 4.77 Billion INR | 31.69% |
| 2018 | 3.62 Billion INR | -30.97% |
| 2017 | 5.24 Billion INR | 14.09% |
| 2016 | 4.6 Billion INR | 9.83% |
| 2015 | 4.18 Billion INR | 26.88% |
| 2014 | 3.3 Billion INR | -19.87% |
| 2013 | 4.12 Billion INR | -4.97% |
| 2012 | 4.33 Billion INR | -15.31% |
| 2011 | 5.12 Billion INR | 15.26% |
| 2010 | 4.44 Billion INR | -42.6% |
| 2009 | 7.73 Billion INR | 7.13% |
| 2008 | 7.22 Billion INR | 14.99% |
| 2007 | 6.28 Billion INR | 11.99% |
| 2006 | 5.6 Billion INR | 72.34% |
| 2005 | 3.25 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 2.45 Billion INR | 0.0% |
| 2023 Q2 | 13.63 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 2.45 Billion INR | -82.08% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 13.7 Billion INR | 23.44% |
| 2022 Q4 | 13.7 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 12.42 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 11.1 Billion INR | 27.74% |
| 2021 Q2 | 8.81 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 11.1 Billion INR | 0.0% |
| 2020 FY | 8.69 Billion INR | 82.1% |
| 2020 Q2 | 4.66 Billion INR | 0.0% |
| 2020 Q4 | 8.69 Billion INR | 0.0% |
| 2019 FY | 4.77 Billion INR | 31.69% |
| 2019 Q2 | 4.95 Billion INR | 0.0% |
| 2019 Q4 | 4.77 Billion INR | 0.0% |
| 2018 FY | 3.62 Billion INR | -30.97% |
| 2018 Q4 | 3.62 Billion INR | 0.0% |
| 2018 Q2 | 5.19 Billion INR | 0.0% |
| 2017 FY | 5.24 Billion INR | 14.09% |
| 2017 Q2 | 5.77 Billion INR | 0.0% |
| 2017 Q4 | 5.24 Billion INR | 0.0% |
| 2016 FY | 4.6 Billion INR | 9.83% |
| 2016 Q4 | 4.6 Billion INR | 0.0% |
| 2016 Q2 | 3.25 Billion INR | 0.0% |
| 2015 FY | 4.18 Billion INR | 26.88% |
| 2015 Q4 | 4.18 Billion INR | 0.0% |
| 2015 Q2 | 4.3 Billion INR | 0.0% |
| 2014 Q2 | 3.75 Billion INR | 0.0% |
| 2014 FY | 3.3 Billion INR | -19.87% |
| 2014 Q4 | 3.3 Billion INR | 0.0% |
| 2013 Q2 | 4.59 Billion INR | 0.0% |
| 2013 Q4 | 4.12 Billion INR | 0.0% |
| 2013 FY | 4.12 Billion INR | -4.97% |
| 2012 FY | 4.33 Billion INR | -15.31% |
| 2012 Q4 | 4.33 Billion INR | 0.0% |
| 2011 Q4 | 5.12 Billion INR | 0.0% |
| 2011 FY | 5.12 Billion INR | 15.26% |
| 2010 FY | 4.44 Billion INR | -42.6% |
| 2009 FY | 7.73 Billion INR | 7.13% |
| 2008 FY | 7.22 Billion INR | 14.99% |
| 2007 FY | 6.28 Billion INR | 11.99% |
| 2006 FY | 5.6 Billion INR | 72.34% |
| 2005 FY | 3.25 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 1.35 Billion INR | -81.063% |
| Biocon Limited | 129.32 Billion INR | 98.101% |
| Blue Jet Healthcare Limited | 3.79 Million INR | -64704.749% |
| Concord Biotech Limited | 18.87 Million INR | -12915.898% |
| FERMENTA BIOTECH LIMITED | 425.36 Million INR | -477.417% |
| GENOMIC VALLEY BIOTECH LIMITED | - INR | -Infinity% |
| Lyka Labs Limited | 429.06 Million INR | -472.428% |
| Panacea Biotec Limited | 209.9 Million INR | -1070.129% |
| SAMSRITA LABS LIMITED | - INR | -Infinity% |
| Servoteach Industries Limited | 5059.00 INR | -48549020.38% |
| SMS Lifesciences India Limited | 331.45 Million INR | -641.017% |
| Supriya Lifescience Limited | 50.2 Million INR | -4792.629% |
| Syngene International Limited | 1 Billion INR | -145.61% |
| TAKE Solutions Limited | 7.5 Million INR | -32648.0% |
| Titan Biotech Limited | 4.53 Million INR | -54082.66% |
| Transgene Biotek Limited | 50.79 Million INR | -4735.318% |
| Vanta Bioscience Limited | 488.01 Million INR | -403.285% |